3THOMPSON S R,NOVICK D,STOCK C J,et al.Free Interleukin (IL)-18 levels,and the impact of IL-18 and IL-18BP genetic variation,in CHD patients and healthy men[J].Arterioscler Thromb Vasc Biol,2007,27(12):2743.
4NOVICK D,DINARELLO C A,RUBINSTEIN M.Soluble IL-18 receptor in human urine:characterization and purification (abstract)[J].Cytokine,1997,9:963.
5MALLAT Z,CORBAZ A,SCOAZEC A,et al.Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability[J].Circulation,2001,104(14):1598-1560.
6WENGER N K,LEWIS S J,WELTY F K,et al.Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study[J].Heart,2008,94(4):434-439.
7MACH F.Inflammation is a crucial feature of atherosclerosis and a potential target to reduce cardiovascular events[J].Handb Exp Pharmacol,2005,(170):697-722.
8ENDRES M.Statins:potential new indications in inflammatory conditions[J].Atheroscler Suppl,2006,7(1):31-35.
9Song Y,Manson J E,Meigs J B,et al.Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women[J].Am J Cardiol,2007,100:1654-1658.
10Sundstrom J,Risérus U,Byberg L,et al.Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality:prospective,population based cohort study[J].BMJ,2006,332:878-882.
